Elevated cAMP levels in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells attenuate the doxorubicin-induced p53 accumulation and protect cells against apoptosis. cAMP responsive element binding protein (CREB) is a cAMP-stimulated transcription factor that regulates genes whose deregulated expression cooperate in oncogenesis. In the present study, we investigated the role of CREB on inhibitory effect of cAMP on apoptosis and p53 accumulation in BCP-ALL NALM-6 cells. To determine whether targeting CREB can modulate the effect of cAMP on doxorubicin-induced apoptosis, we knocked down CREB in NALM-6 cells using lentiviral CREB shRNA. Knocked down cells were treated with doxorubicin in the presence or absence of cAMP-elevating agents. p53 protein level and apoptosis were assessed by western blot analysis and flow cytometry, respectively. p53 protein expression was reduced in cells treated with combination of cAMPelevating agents and doxorubicin in contrast to cells treated with doxorubicin alone even in CREB-knocked down cells. Apoptosis assay showed that the cAMP-elevating agents decreased doxorubicin-induced apoptosis in CREB-knocked down and control cells. Although, CREB plays a particularly important role in cAMP signaling pathway our data suggest that CREB does not mediate the inhibitory effect of cAMP on doxorubicin-induced apoptosis and p53 accumulation in BCP-ALL NALM-6 cells. 
poor outcome in patients with AML (3) . Moreover, suppression of CREB inhibits leukemic cell growth and induces apoptosis in some malignant conditions (4) . In response to various signals such as growth factors, peptide hormones and neuronal activity CREB can be activated through phosphorylation at Ser133 by cAMP-dependent protein kinase A (5).
cAMP is an important intracellular second messenger that mediates a wide variety of biologically distinct cellular processes including metabolism, cell differentiation, and apoptosis (6) .
It has been shown that cAMP signaling pathway can impede drug-induced apoptosis in leukemiccells (7) . Likewise, downregulation of cAMP inhibits tumor growth and improve the effectiveness of anti-cancer drugs in treatment of glioblastoma and in killing glioblastoma stem cells (8) . Previous studies have revealed that elevated levels of cAMP inhibit doxorubicin-induced apoptosis by dephosphor-ylation of p53 serine residues and attenuation of the p53 accumulation in BCP-ALL cells (9) . In normal unstressed cells, p53 is present at low levels (10) . In response to various cellular stresses such as DNA damage, oncogene overexpression, heat shock, and hypoxia, p53
becomes activated, that results in p53 protein level augmentation and transactivity (11) . Activation of p53 determines the fate of the cell through various functions including cell cycle arrest, apoptosis, DNA repair and senescence (12) . Anthracyclines such as doxorubicin that are used in treatment of ALL patients induce p53 accumulation in leukemic cells which can result in apoptosis (13) . As CERB plays a critical role in mediating the cAMP effects, we hypothesized that cAMP exerts its inhibitory effect on p53 accumulation and apoptosis through CREB protein. To this end, CREB was knocked down using lentiviral CREB shRNAin BCP-ALL NALM-6 cells. (14) .
Material and methods

Cell culture
Lentivirus production and infection
The day before transfection, 3 × 10 6 HEK- 
Statistical analysis
Data were analyzed using two-tailed student ttest. A p-value of <0.05 was considered to be statistically significant.
Results
Elevated cAMP levels attenuate the doxorubicininduced apoptosis in NALM-6 cells
In the present study, NALM-6 cells were treated with doxorubicin in the presence or absence of the cAMP-increasing agents, forskolin and IBMX. Then, sub-G1 DNA content analysis was performed using flow cytometry. As shown in Fig.   1A and 1B, cell population in sub-G1 phase was Taken together, these findings demonstrated that elevation of cAMP levels reduced the doxorubicininduced apoptosis in NALM-6 cells.
CREB knock down was not sufficient to prevent the inhibitory effect of cAMP on doxorubicinmediated apoptosis
To ascertain the probable contribution of CREB in the suppressive effect of cAMP on doxorubicin-induced apoptosis, NALM-6 cells were transduced with lentiviruses expressing either the shRNA targeting CREB or scrambled control shRNA as described previously. As shown in Fig . At 48 h after removal of the virus-containing medium, cells were harvested for total RNA extraction. CREB mRNA expression was measured using quantitative RT-PCR and normalized to the expression of GAPDH (n = 3; * P=0.014 for CREB-shRNA2 and 0.001 for CREB-shRNA3 relative to cells treated with Ctrl-shRNA). B:at 48 h after removal of the virus-containing supernatant cells were harvested for protein extraction. CREB protein levels were assessed by Western blot analysis. Equal sample loading was verified by β-actin. C: at 48 h after replacement of lentiviral supernatant with standard growth medium, transduction efficiency was assessed by evaluation of GFP expression in NALM-6 cells. D, E:CREB-knocked down and control cells were treated with forskolin/IBMX 30 min prior to the addition of doxorubicin for 24 h. Cells were harvested and sub-G1 cell population was measured by flow cytometry(n = 3; *P=0.0٠7 for Ctrl-shRNA+ (Dox+F+I) relative to cells treated with Ctrl-shRNA+Dox, P=0.019 for CREB-shRNA3+ (Dox+F+I) relative to cells treated with CREB-shRNA3+Dox). F, G:CREB-knocked down and control cells were treated with indicated agents for 24 h. Apoptotic cells were qualified using annexin-V and FACS analysis (n = 3; * P=0.046 for Ctrl-shRNA + (Dox+F+I) relative to cells treated with Ctrl-shRNA+Dox, P=0.022 for CREB-shRNA3+ (Dox+F+I) relative to cells treated with CREB-shRNA3+Dox). 
